Check!ng: The last frontier for Harm Reduction in party settings;Check!ng: A última fronteira para a Redução de Riscos em contextos festivos

Saude e Sociedade

Volumn 24, Issue 2, 2015, Pages 646-660

  Martins, Daniel ^a   Valente, Helena ^a   Pires, Cristiana ^a  

^a INSTITUTO PIAGET   (Portugal)

Author keywords

Drug checking; Harm minimization; Outreach work; Party settings; Psychoactive substances; Risk reduction

Indexed keywords

EID: 84931829410     PISSN: 01041290     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-12902015000200020     Document Type: Article

References (36)

1. BENSCHOP, A.; RABES, M.; KORF; D. J. Pill testing, ecstasy and prevention: a scientific evaluation in three European cities. Amsterdam: Rozenberg, 2002.
2. BOSSONG, M. G.; VAN DIJK, J. P.; NIESINK, R. J. Methylone and mCPP, two new drugs of abuse? Addiction Biology, Hoboken, v. 10, n. 4, p. 321-323, 2005
3. BOSSONG, M. G. et al. mCPP: an undesired addition to ecstasy market. Journal of Psychopharmacology, Oxford, v. 24, n. 9, p. 1395-1401, 2010.
4. BRUNT, T. M. et al. An analysis of cocaine powder in the Netherlands. Addiction, Oxford, v. 104, n. 5, p. 798-805, 2009
5. CALADO, V. G. Drogas sintéticas: mundos culturais, trance e ciberespaço. Lisboa: Instituto da Droga e da Toxicodependência, 2006
6. Caudevilla-Gálligo, F. et al. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. Journal of Psychopharmacology, Oxford, v. 26, n. 7, p. 1026-1035, 2012.
7. COLE, C. et al. CUT: a guide to adulterants, bulking agents and other contaminants found in illicit drugs. Liverpool: John Moores University, 2010.
8. COSTA, E. M. Redução de danos: preconceitos, obstáculos, justificação. Toxicodependências, Lisboa, v. 7, n. 3, p. 53-58, 2001.
9. CRUZ, O.; MACHADO, C. Consumo “não problemático” de drogas ilegais. Toxicodependências, Lisboa, v. 16, n. 2, p. 39-47, 2010.
10. DEA - DRUG ENFORCEMENT ADMINISTRATION. Blotter acid mimic (actually containing a mixture of 4-chloro-2,5-dimethoxyamphetamine and 4-bromo-2,5-dimethoxyamphetamine) in Warner Robins, Georgia. Microgram Bulletin, Washington, DC, v. 42, n. 3, p. 23-32, 2009.
11. DUBACH, U.; ROSNER, B.; STÜRMER T. An epidemiologic study of abuse of analgesic drugs: effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). The New England Journal of Medicine, Boston, v. 324, p. 155-160, jan. 1991.
12. EMCDDA - EUROPEAN CENTRE FOR DRUGS AND DRUG ADDICTION. An inventory of on-site pill-testing interventions in the EU. Lisbon, 2001.
13. EMCDDA - EUROPEAN CENTRE FOR DRUGS AND DRUG ADDICTION. Relatório anual 2010. Lisboa, 2010.
14. EMCDDA - EUROPEAN CENTRE FOR DRUGS AND DRUG ADDICTION. Statistical bulletin 2011: price and purity information: table ppp9 - composition of synthetic schedule illicit drugs. Lisbon, 2011.
15. EROWID CREW. Cocaine adulterated with levamisole on the rise: status as of september 2009. [S.l.]: Erowid, 2009. Disponível em: . Acesso em: 1 de out. 2009
16. EUROPOL- SERVIÇO EUROPEU DE POLÍCIA; EMCDDA - EUROPEAN CENTRE FOR DRUGS AND DRUG ADDICTION. Active monitoring report: a new psychoactive substance: 1-(3-chlorophenyl) piperazine (mCPP). Lisbon, 2009.
17. FERNANDES, J. L.; PINTO, M.; OLIVEIRA, M. Caracterização e análise crítica das práticas de RRMD na área das drogas em Portugal. Toxicodependências, Lisboa, v. 12, n. 2, p. 71-82, 2006.
18. FERNANDES, J. L.; RIBEIRO, C. RRMD, estilos de vida junkie e controlo social. Sociologia, Problemas e Práticas, Lisboa, n. 39, p. 57-68, ago. 2002.
19. FRY, E.; LEVI, J. Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs. New York: Springer-Verlag, 2009.
20. GAMMA, A. et al. Is ecstasy perceived to be safe?: a critical survey. Drug Alcohol Dependence, Limerick, v. 77, n. 2, p. 185-193, 2004.
21. HASSAL, A. H.: Food and its adulterations: comprising the reports of the Analytical Sanitary Commission of “The Lancet” for the years 1851 to 1854 inclusive, revised of original microscopical and chemical anal. London: Lancet Analytical Sanitary Commission, 1901.
22. HEALTH ADVISORY. Delaware Health Alert Network #102: September 2, 2005. Delaware: Delaware Health and Social Services, 2005. Disponível em: Acesso em: 01 de Dez. 2011.
23. HIDALGO, E. Hacia la percepción de riesgo basada en la evidencia. El Rosario: IEA, 2004. Disponível em: . Acesso em: 01 de Dez. 2011.
24. HUNGERBUEHLER, I.; BUECHELI, A.; SCHAUB, M. Drug checking: a prevention measure for a heterogeneous group with high consumption frequency and polydrug use – evaluation of Zurich’s drug checking services. Harm Reduction Journal, London, v. 8, n. 16, p. 1477-7517, 2011. Disponível em: Acesso em: 1 dez. 2011.
25. JOHNSTON, J. et al. A survey of regular ecstasy users’ knowledge and practices around determining pill content and purity: implications for policy and practice. International Journal of Drug Policy, Amsterdam, v. 17, p. 464-472, dez. 2006.
26. MARLATT, G. A. Harm reduction: come as you are. Addictive Behaviors, Oxford, v. 21, n. 6, p. 779-788, 1996.
27. PORTUGAL. Presidência do Conselho de Ministros. Decreto-lei nº 183, de 21 junho de 2001. Diário da República, Lisboa, 21 jun. 2001. Série A, n. 142, p. 3594-3601.
28. PREBLE, E.; CASEY, J. Taking care of business: the heroin user’s life on the street. International Journal of the Addictions, New York, v. 4, n. 1, p. 1-24, 1969.
29. ROSEMBERG, P. H.; VEERING, B. T.; URMEY, W. F. Maximum recommended doses of local anesthetics: a multifactorial concept. Regional Anesthesia and Pain Medicine, Philadelphia, v. 29, n. 6, p. 564-575, 2004.
30. SHULGIN, A. T.; SHULGIN, A. TiHKAL: the continuation. Berkeley: Transform Press, 1997.
31. TEDI - TRANS-EUROPEAN DRUG INFORMATION PROJECT. TTR3: composition & adulteration of tested samples: tedi trend report #3. Barcelona, 2013.
32. USDHHS - U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES. Agranulocytosis associated with cocaine use: four states, March 2008 - November 2009. Morbidity and Mortality Weekly Report. Atlanta, v. 58, n. 49, p. 1381-1385, 2009.
33. WINSTOCK, A. R.; MARSDEN, J. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone). Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2010.
34. WINSTOCK, A. R.; WOLFF, K.; RAMSEY, J. Ecstasy pill testing: harm minimization gone too far? Addiction, Oxford, v. 96, n. 8, p. 1139–1148, 2001.
35. WOOD, D. M.; DARGAN, P. I. Mephedrone. In: WINSTOCK, A. R.; WOLFF, K.; RAMSEY, J. (Ed.). Novel psychoactive substances. Boston: Academic Press, 2013. p. 211-231
36. ZHU, N. Y.; Le GATT D. F.; TURNER, A. R.: Agranulocytosis after consumption of cocaine adulterated with levamisole. Annals of Internal Medicine, Philadelphia, v. 150, n. 4, p. 287-289, 2009.